Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine in a Multicenter Cohort of Nursing Home Residents Receiving Maintenance Hemodialysis
(2021) American Journal of Kidney Diseases — Vol. 78, n° 5, p. 766-768 (2021)
Files
LabriolaetalImmunogenicityofBNT162b2SARS-CoV-2VaccineinaMulticenterCohortof.pdf
Open Access - Adobe PDF
- 655.99 KB
Details
- Authors
- Abstract
- (en) TO THE EDITORS, We recently reported that almost all maintenance hemodialysis (MHD) patients mount specific antibodies within a month of COVID-19 onset. However, evidence concerning the immunogenicity of SARS-CoV-2 vaccines in this immunodeficient population is scarce. [...]
- Affiliations
Citations
Labriola, L., Scohy, A., Van Regemorter, E., Robert, A., Clerbaux, G., Gillerot, G., Pochet, J.-M., Biller, P., De Schuiteneer, M., Morelle, J., Yombi, J. C., Kabamba-Mukadi, B., Rodriguez-Villalobos, H., & Jadoul, M. (2021). Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine in a Multicenter Cohort of Nursing Home Residents Receiving Maintenance Hemodialysis. American Journal of Kidney Diseases, 78(5), 766-768. https://doi.org/10.1053/j.ajkd.2021.07.004 (Original work published 2021)